To Evaluate The Efficacy Of Trimurti Agada And Vishghna Lepa In The Management Of Dushivishajanya Dadru With Special Reference To Recurrent Tinea

A Clinical Study To Evaluate The Efficacy Of internally Trimurti Agada And externally Vishghna Lepa In The Management Of Dushivishajanya Dadru With Special Reference To Recurrent Tinea A Single Arm Open Labelled Clinical Trial - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/090731

Enrollment

Registered

2025-07-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L530- Toxic erythema

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: This trial will include all the patients of Dadru having classical signs and symptoms like, Kandu (Itching), Raga (Erythema), Pidaka (Papillae), Mandalamudgatama (Discoid lesion with elevated border) along with sign and symptoms of Dushivisha like., Dhatukshaya, Vaivarnya, Avipaka, Arochaka irrespective of gender, religion, profession, socioeconomic stat Dadru which are Recurrent in nature (minimum 2 times in a year). Patient willing to accept the participation in the clinical trial.

Exclusion criteria

Exclusion criteria: Patient suffering from severe, or complicated systemic disease like, Chronic kidney disease, Liver disease and VDRL disease will be excluded from the trial study. Dadru which are newly originated (Recurrent rate Less than 2 times in year). Patients who are not willing for inclusion in the study. Pregnant women

Design outcomes

Primary

Measure	Time frame
The patient will be withdrawn from the study if patient complains of any adverse reaction, not responding to the treatment or any serious complication occur due to treatment will be referred to the higher center. Between the trial period; if any serious complication develops requiring urgent treatment such as pyoderma, prolonged fever due to infected skin lesions, patients will be referred appropriately.Timepoint: 60 days	—

Measure

Time frame

The patient will be withdrawn from the study if patient complains of any adverse reaction, not responding to the treatment or any serious complication occur due to treatment will be referred to the higher center. Between the trial period; if any serious complication develops requiring urgent treatment such as pyoderma, prolonged fever due to infected skin lesions, patients will be referred appropriately.Timepoint: 60 days

—

Secondary

Measure	Time frame
To study the efficacy of Trimurti agada and vishgna lepa in recurrent tinea in every 15 days Till 60daysTimepoint: 60 days	—

Countries

India

Contacts

Public ContactDr Ganesh venktarajam Mamidala

Sumatibhai Shah Ayurved mahavidyalaya hadpsar

khankhanemanohar@rediffmail.com918888763651

Outcome results